New pill tested to fight hepatitis b virus
NCT ID NCT04536337
Summary
This early-stage study tested a new oral medication called ALG-000184 for people with chronic hepatitis B. The main goals were to see if the drug is safe, how the body handles it, and if it can lower the amount of hepatitis B virus in the blood. The study involved healthy volunteers and people with hepatitis B, comparing the new drug to a placebo (inactive pill) and to a standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACS
Auckland, New Zealand
-
CAP Research
Quatre Bornes, Mauritius, 72218, Mauritius
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
-
Prince of Wales
Shatin, Hong Kong
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Saint Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
-
Western Health
Footscray, Victoria, 3011, Australia
Conditions
Explore the condition pages connected to this study.